Roche Tasmar for Parkinson's will be available by March following Jan. 29 approval.
ROCHE TASMAR 200 MG T.I.D. REDUCES "OFF" TIME BY THREE HOURS from a baseline of 5.9 hours, according to data from a U.S./Canadian study included in labeling for the Parkinson's disease therapy approved Jan. 29. The 100 mg t.i.d. dose of Tasmar (tolcapone) reduced "off" time by two hours from a 6.4 hour baseline and placebo reduced it by 1.2 hours from 6.2 hours.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth